Abiopharma

New Form 6-K - SciSparc Ltd. Filed: 2025-07-31 AccNo: 0001213900-25-069979 Size: 55 KB

New Form SCHEDULE 13G - Replimune Group, Inc. Filed: 2025-07-31 AccNo: 0000902664-25-003286 Size: 17 KB

New Form 8-K - RESMED INC Filed: 2025-07-31 AccNo: 0001193125-25-170512 Size: 450 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form NT 20-F - Akso Health Group Filed: 2025-07-31 AccNo: 0001213900-25-069980 Size: 22 KB

iSpecimen Inc. Announces Pricing of Approximately $1.75 Million Private Placement Priced At-the-Market

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

Guardant Health, Inc. - Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference

ATEC - ATEC Reports Second Quarter 2025 Financial Results and Raises Full-Year Guidance

New Form 4 - Cardiff Oncology, Inc. Filed: 2025-07-31 AccNo: 0000950170-25-100882 Size: 6 KB

New Form SCHEDULE 13D/A - Abivax S.A. Filed: 2025-07-31 AccNo: 0001104659-25-072677 Size: 25 KB

New Form 4 - GeneDx Holdings Corp. Filed: 2025-07-31 AccNo: 0001415889-25-020713 Size: 9 KB

P3 Health Partners Schedules Second Quarter 2025 Earnings Release and Conference Call

Envista Reports Second Quarter 2025 Results

Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025